Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM)
SAN DIEGO, April 13, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today its filing with the U.S. Food & Drug Administration ("FDA") requesting orphan drug designation for RayVa™, the Company's drug candidate indicated for the treatment of Raynaud's phenomenon in patients with systemic sclerosis.